Houston TX 骨髓纤维化临床试验
19项针对 骨髓纤维化的研究正在 Houston及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
招募中1/2 期
- MD Anderson Cancer Center, Houston
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
招募中3 期
- MD Anderson Cancer Center, Houston
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
招募中1 期
- The University of Texas, MD Anderson Cancer Center, Houston
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
招募中3 期
- MD Anderson Cancer Center, Houston
- The University of Utah-Huntsman Cancer Institute, Houston
- LUMI Research, Houston
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
招募中1/2 期
- MD Anderson, Houston
A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
招募中1 期
- MD Anderson Cancer Center, Houston
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
招募中2 期
- MD Anderson Cancer Center, Houston
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
招募中1 期
- University of Texas M. D. Anderson Cancer Center, Houston
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
招募中1/2 期
- The University of Texas M. D. Anderson Cancer Center, Houston
Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
招募中1/2 期
- MD Anderson Cancer Center, Houston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
招募中1 期
- MD Anderson Cancer Center, Houston
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
招募中2 期
- GSK Investigational Site, Houston
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
招募中1 期
- Md Anderson Cancer Center, Houston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
招募中2 期
- MD Anderson, Houston
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
招募中2 期
- MD Anderson, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中观察性研究
- Massive Bio SYNERGY-AI site, Houston
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
招募中3 期
- U.T. MD Anderson Cancer Center, Houston
Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
招募中1 期
- The University of Texas MD Anderson Cancer Center, Houston
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
招募中1/2 期
- The University of Texas MD Anderson Cancer Center, Houston
其他城市的 骨髓纤维化试验
- New York City, NY18 项研究
- Boston, MA12 项研究
- Durham, NC12 项研究
- Columbus, OH11 项研究
- Seattle, WA11 项研究
- Miami, FL10 项研究
- Salt Lake City, UT10 项研究
- Atlanta, GA9 项研究
- Tampa, FL9 项研究
- Nashville, TN9 项研究
- Cleveland, OH9 项研究
- Baldwin Park, CA9 项研究
Houston的其他研究
- 非小细胞肺癌145 项研究
- 乳腺癌126 项研究
- 癌症（所有类型）121 项研究
- 转移性癌症104 项研究
- 结直肠癌102 项研究
- 卵巢癌89 项研究
- 急性髓系白血病85 项研究
- 肺癌78 项研究
- 前列腺癌76 项研究
- 子宫内膜癌68 项研究
- 胰腺癌61 项研究
- 黑色素瘤59 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月5日。每项研究自行设定入选标准，由研究团队决定谁能参与。